IL17A and diabetes mellitus: Notably, although not assessing inflammation in patients with diabetes, in a systematic review assessing the role of GLP‐1RAs in patients with HS, GLP‐1RAs were found to reduce TNF‐α, IL‐17, and NF‐κB levels in patients [23].